Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
New England Journal of Medicine · 13.07.2023 · 389 (2) · 137-147
DOI: 10.1056/nejmoa2304594 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 13.07.2023. Verfasst von Masahiro Tsuboi und 20 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), the Department of Thoracic Oncology, Kana…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, COVID-19, Lung Neoplasms. Die Arbeit wurde bisher 699-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Section of Me…
ORCID-Profile: Jonathan W Goldman
Förderung
- AstraZeneca
Zitieren
APA
Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Su, W. C., de Marinis, F., Shepherd, F. A., Lee, K. H., Le, N. T., Dechaphunkul, A., Kowalski, D., Poole, L., Bolanos, A., Rukazenkov, Y., …, & ADAURA Investigators (2023). Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC. New England Journal of Medicine, 389(2), 137-147. https://doi.org/10.1056/nejmoa2304594
Vancouver
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, et al. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC. New England Journal of Medicine. 2023;389(2):137-147. doi:10.1056/nejmoa2304594
BibTeX
@article{Tsuboi2023,
author = {Tsuboi, Masahiro and Herbst, Roy S and John, Thomas and Kato, Terufumi and Majem, Margarita and Grohé, Christian and Wang, Jie and Goldman, Jonathan W and Lu, Shun and Su, Wu-Chou and de Marinis, Filippo and Shepherd, Frances A and Lee, Ki Hyeong and Le, Nhieu Thi and Dechaphunkul, Arunee and Kowalski, Dariusz and Poole, Lynne and Bolanos, Ana and Rukazenkov, Yuri and Wu, Yi-Long and ADAURA Investigators, ADAURA Investigators},
title = {Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {2},
pages = {137--147},
doi = {10.1056/nejmoa2304594}
}
EUVIMED